1. Home
  2. NOVTU vs BCTXL Comparison

NOVTU vs BCTXL Comparison

Compare NOVTU & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novanta Inc. Tangible Equity Units

NOVTU

Novanta Inc. Tangible Equity Units

N/A

Current Price

$61.08

Market Cap

0.0

Sector

Miscellaneous

ML Signal

N/A

Logo BriaCell Therapeutics Corp. Warrant expiring 2031

BCTXL

BriaCell Therapeutics Corp. Warrant expiring 2031

N/A

Current Price

$0.89

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NOVTU
BCTXL
Founded
N/A
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
1999
2025

Fundamental Metrics

Financial Performance
Metric
NOVTU
BCTXL
Price
$61.08
$0.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2K
13.2K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.82
N/A
Revenue
$521,290,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$75.48
N/A
Revenue Growth
35.49
N/A
52 Week Low
$47.57
$0.61
52 Week High
$76.95
$1.40

Technical Indicators

Market Signals
Indicator
NOVTU
BCTXL
Relative Strength Index (RSI) 42.96 45.20
Support Level $59.02 $0.75
Resistance Level $61.73 $1.11
Average True Range (ATR) 0.86 0.07
MACD -0.06 -0.01
Stochastic Oscillator 30.67 0.04

Price Performance

Historical Comparison
NOVTU
BCTXL

About NOVTU Novanta Inc. Tangible Equity Units

Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.

About BCTXL BriaCell Therapeutics Corp. Warrant expiring 2031

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: